Welcome! This is the NEW free version of the SciBITES Pharma News Engine from SciBite. By using this site you to accept our Terms & Conditions which the use of cookies to enhance your user experience.


Here is the latest news for your query in chronological order, most recent articles at the top. Use the options on the right to filter and customise this news feed.

  Todays Pfizer (Tag) Articles ...

High resolution molecular and histological analysis of renal disease progression in ZSF1 fa/faCP rats, a model of type 2 diabetic nephropathy.
Medline, PloS one [12] e0181861, 28-Jul-2017
A Phase 1, Randomized, Double-blind, Placebo-controlled Study To Assess The Safety, Tolerability, And Pharmacokinetics Of Multiple Escalating Oral Doses Of Pf-06865571 In Healthy, Including Overweight And Obese, Adult Subjects
ClinicalTrials.gov, , 28-Jul-2017
Pfizer's Worrying Trend
https://seekingalpha.com, , 27-Jul-2017
Cross-sectional Study of Bone Density, Bone Microarchitecture, Vertebral Fractures and Trabecular Bone Score in Patients With Acromegaly Treated With Pegvisomant Compared to Patients With Untreated Active Acromegaly
ClinicalTrials.gov, , 27-Jul-2017
Pfizer Doesn't Want To Be Left In the Dust Of Avastin Biosimilar
https://seekingalpha.com, , 26-Jul-2017
Lilly's baricitinib setback gives Pfizer's Xeljanz a clear shot at newer rivals
http://www.fiercepharma.com, , 26-Jul-2017
Pfizer announces positive top-line results from the comparative REFLECTIONS B7391003 study for PF-06439535, a potential biosimilar to Avastin® (bevacizumab)
http://www.worldpharmanews.com, , 26-Jul-2017
Pfizer announced positive results from the comparative study for PF-06439535, a potential biosimilar to Avastin
http://www.biosimilarnews.com, , 26-Jul-2017
Phase I/II Study to Evaluate the Safety and Tolerability of Avelumab in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
ClinicalTrials.gov, , 26-Jul-2017
ViiV Healthcare Announces Superior Efficacy of Dolutegravir Versus Lopinavir/Ritonavir in Second-line HIV Treatment in Resource-limited Settings
http://www.prnewswire.com, , 25-Jul-2017
Ophthalmic Drugs Market to Reach US$34.3 Billion by 2025: Players Entering Into Co-development Agreements to Enhance Product Portfolio
http://www.prnewswire.com, , 25-Jul-2017
Dermatological Drugs Market Forecast 2017-2027
http://www.prnewswire.com, , 25-Jul-2017
ViiV Healthcare Announces Superior Efficacy of Dolutegravir Versus Lopinavir/Ritonavir in Second-line HIV Treatment in Resource-limited Settings

  This Weeks Pfizer (Tag) Articles ...

EMA’s CHMP Issues Positive Opinion for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma
http://www.bionity.com, , 25-Jul-2017
APIXABAN FORMULATIONS
US/WO/EU Patents, , 25-Jul-2017
Pyrazolopyrimidine Compounds
US/WO/EU Patents, , 25-Jul-2017
DOSAGE FORMS OF APIXABAN
US/WO/EU Patents, , 25-Jul-2017
APIXABAN FORMULATIONS
Merck, Pfizer collaborate with Corning on pharmaceutical glass packaging
http://www.centerwatch.com, , 24-Jul-2017
Pesquisa da Pfizer revela que brasileiros com disfunção erétil planejam dia e hora para relações sexuais
http://www.prnewswire.com, , 24-Jul-2017
Showing Records 0 ... 20  


SciBite
The Language Of Science

SciBite provides text-analytics and data intelligence software for drug discovery, clinical and competitor intelligence and much more for pharma, healthcare and life sciences.

This is a Limited, Free Service only touching the surface of how SciBite's tools transform biomedical text, literature, patents, internal documents and news into a rich intelligence network. If you'd like to know more, contact us to see how our tools can transform your work today!

Topic Activity & Tools

Get Daily Alerts!

Click For Email & RSS Alerts

About/Links

Name: Pfizer (Tag)
Type: Company

Filters

Source:


Must Mention A:


In Context:


Insights

Show Most Frequent


Optional, Only Include Source:


Tools

[Not available (Why?)]